论文部分内容阅读
目的:探讨Ⅱ期非小细胞肺癌(NSCLC)组织中Ⅲ型β微管蛋白(β-tubulin-Ⅲ)和Stathmin基因mRNA表达与诺维本+顺铂(NP)方案化疗敏感性的关系,为个体化治疗方案的制定提供依据。方法:单基因定量法检测73例已手术Ⅱ期NSCLC患者癌组织中β-tubulin-Ⅲ和Stathmin的mRNA表达。所有患者行NP方案化疗,并随访患者的无瘤生存时间(DFS)和总生存时间(OS),统计学分析β-tubulin-Ⅲ和Stathmin的mRNA表达水平与患者DFS和OS的关系。结果:73例患者的OS与β-tubulin-Ⅲ的mRNA表达水平有关,P=0.003。患者的DFS与β-tubulin-Ⅲ的表达及淋巴结转移情况有关,P<0.01。绘制生存曲线表明,癌组织中β-tubulin-Ⅲ低表达患者的OS和DFS均高于β-tubulin-Ⅲ高表达者,P<0.05;Stathmin低表达患者的OS和DFS与高表达患者相比,差异均无统计学意义,P>0.05。结论:Ⅱ期NSCLC患者癌组织中,β-tubulin-Ⅲ表达水平可以作为预测患者预后及化疗敏感性的指标,可作为选择合适化疗药物的参考。
OBJECTIVE: To investigate the relationship between the expression of β-tubulin-Ⅲ and Stathmin mRNA in NSCLC patients and the sensitivity to chemotherapy with Novubiben and cisplatin (NP) Individual treatment programs to provide a basis for the formulation. Methods: The mRNA expressions of β-tubulin-Ⅲ and Stathmin in 73 cases with stage Ⅱ NSCLC were detected by single gene quantitative method. All the patients underwent chemotherapy with NP regimen. The patients were followed up for DFS and OS. The relationship between β-tubulin-Ⅲ and Stathmin mRNA expression and DFS and OS was analyzed. Results: The OS of 73 patients was related to the mRNA expression level of β-tubulin-Ⅲ, P = 0.003. DFS in patients with β-tubulin-Ⅲ expression and lymph node metastasis, P <0.01. The survival curves showed that OS and DFS in patients with low expression of β-tubulin-Ⅲ in cancer tissues were significantly higher than those with high β-tubulin-Ⅲ expression (P <0.05). OS and DFS in patients with low expression of Stathmin were significantly higher than those in patients with high expression , The differences were not statistically significant, P> 0.05. Conclusion: The expression of β-tubulin-Ⅲ in stage Ⅱ NSCLC patients can be used as an index to predict the prognosis and chemosensitivity of patients, which can be used as a reference for selecting appropriate chemotherapeutics.